Palvella Therapeutics (PVLA) Q4 2024 earnings summary

Executive summary

• Mission is to serve patients with serious rare genetic skin diseases lacking FDA-approved therapies, aiming to be first to market with novel treatments.

• Completed merger and $78.9M private placement, transforming into a publicly traded rare disease biopharma with a late-stage pipeline.

• Advanced QTORIN rapamycin into Phase 3 SELVA (microcystic LMs) and Phase 2 TOIVA (cutaneous VMs) studies, with multiple FDA designations including Breakthrough Therapy, Orphan Drug, and Fast Track for microcystic LMs.

• Cash position of $83.6M as of December 31, 2024, expected to fund operations into H2 2027.

• Strong support from institutional investors and FDA orphan product grant for Phase 3 study.

Financial highlights

• Cash and cash equivalents as of December 31, 2024, were $83.6 million.

• Net loss of $17.4 million, or $7.83 per diluted share for 2024, compared to net income of $17.9 million, or $2.19 per diluted share in 2023.

• R&D expenses were $8.2 million in 2024, down from $8.8 million in 2023; G&A expenses rose to $5.9 million from $3.1 million.

• Expect to end 2025 with at least $55 million in cash, with $30 million total cash spend projected for the year.

• Shares outstanding as of year-end: 13,687,830 (including common and equivalents).

Outlook and guidance

• Cash runway extends into the second half of 2027, covering major milestones including Phase 3 and Phase 2 trial completions, NDA submission, and two new pipeline programs.

• R&D spend expected to increase to $18–$20 million in 2025 due to higher clinical activity; G&A spend projected at $10–$12 million.

• Top-line Phase 3 data for MLM expected in Q1 2026; Phase 2 CVM data expected in Q4 2025.

• Plans to unveil a third QTORIN rapamycin indication and a new QTORIN program in the second half of 2025.